CoChat

Glucagon-like Peptide 1 (GLP-1) in the Treatment of Diabetes

Nauck, M. A. · 2004 · Hormone and Metabolic Research

The DOI matches its Crossref record.

Abstract

Glucagon-like peptide 1 (GLP-1) was discovered as an incretin (insulinotropic gut) hormone. Biological actions of GLP-1 in healthy and type 2 diabetic subjects include (a) stimulation of insulin secretion in a glucose-dependent manner, (b) suppression of glucagon, (c) reduction in appetite and food intake, (d) deceleration of gastric emptying. In animal experiments, in addition, (e) stimulation of beta-cell neogenesis, growth and differentiation in animal and tissue culture experiments, and (f) in vitro inhibition of beta-cell apoptosis induced by different agents have been observed. Since the incretin effect--the higher insulin secretory response to oral as compared to intravenous glucose loads - is reduced in patients with Type 2 diabetes, GLP-1 has been used to pharmacologically replace incretin. Intravenous GLP-1 can normalise, and subcutaneous GLP-1 can significantly lower plasma glucose in the majority of patients with Type 2 diabetes. The magnitude of this effect does not greatly depend on patient characteristics such as age, sex, obesity, or baseline insulin and glucagon, with minor influences of previous antidiabetic therapy and actual metabolic control. GLP-1 itself, however, is inactivated rapidly in vivo by the protease DPP IV and can only be used for short-term metabolic control, such as in intensive care units (potentially useful in patients with acute myocardial infarction, coronary surgery, cerebrovascular events, septicaemia, during the perioperative period and while on parenteral nutrition). For more long-term metabolic control, incretin mimetics (agonists at the GLP-1 receptor) with more favourable pharmacokinetic profiles should be used.

Overview

Integrity signals

Registry

Crossref · 10.1055/s-2004-826175

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 72

Metadata

Authors
Nauck, M. A.
Affiliations
Diabeteszentrum Bad Lauterberg (DE)
Corresponding author
Nauck, M. A.
Venue
Hormone and Metabolic Research
Published
2004-11
Volume
36
Issue
11/12
Pages
852-858
ISSN
  • 0018-5043 (ISSN-L)
  • 1439-4286
OpenAlex
W2084139518
Cited by
72
References
0
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 2 · 2013: 2 · 2012: 4
FWCI
4.75
Type
journal article
Language
de
Open access
closed
Locations
  • Hormone and Metabolic Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords
glucagon-like peptide-1, type 2 diabetes, incretin-based therapy, GLP-1 receptor agonists, insulin secretion, glucagon suppression, appetite suppression, gastric emptying, beta-cell neogenesis, beta-cell apoptosis, dipeptidyl peptidase IV, plasma glucose control, intensive care, perioperative care, parenteral nutrition
MeSH terms
Administration, Oral, Animals, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Glucagon, Humans, Hypoglycemic Agents, Infusions, Intravenous, Insulin, Peptide Fragments, Protein Precursors, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like Peptide 1 (GLP-1) in the Treatment of Diabetes. https://app.cochat.ai/papers/10.1055/s-2004-826175
The paper
Nauck, M. A. (2004). Glucagon-like Peptide 1 (GLP-1) in the Treatment of Diabetes. Hormone and Metabolic Research. https://doi.org/10.1055/s-2004-826175

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.